River BioMedics is a cardiovascular drug-discovery firm that combines in-house bio-engineering technology with heart biology to create 3D human cardiac models, including hiPSC-derived 3D cardiac strips. The company is developing a portfolio of disease-modifying small-molecule therapeutics aimed at genetically verified cardiac targets, with an initial emphasis on heart failure with preserved ejection fraction (HFpEF). Its 3D cardiac strip technology is intended to provide in‑vitro human proof-of-concept early in discovery to improve preclinical-to-clinical translation and is applicable to multiple heart conditions. River BioMedics plans to use newly raised capital to advance compound development for its flagship HFpEF programme and to continue work on earlier-stage pipeline projects toward lead selection. In January the company also received EIC funding to scale hiPSC-3D cardiac strips to high-throughput settings and an EIC Pathfinder grant to develop a pumping human Mini-heart as part of a consortium. The company was founded as a University of Twente spin-out and conducts research associated with LUMC.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2023